We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$849M
1-Year Est. Return
470.8%
This Fund
S&P 500
This Quarter
Est. Return
+12.11%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$173M
AUM Growth
+$172M
(+84,096%)
Cap. Flow
+$17.2M
Cap. Flow
% of AUM
9.97%
Top 10 Holdings %
Top 10 Hldgs %
38.32%
Holding
115
New
19
Increased
26
Reduced
33
Closed
31
Top Buys
| 1 |
Cogent Biosciences
COGT
|
+$3.68M |
| 2 |
Fulcrum Therapeutics
FULC
|
+$3.52M |
| 3 |
Cerus
CERS
|
+$3.5M |
| 4 |
Arvinas
ARVN
|
+$3.29M |
| 5 |
NextCure
NXTC
|
+$3.18M |
Top Sells
| 1 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
+$5.49M |
| 2 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
+$2.79M |
| 3 |
MSAC
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
|
+$2.54M |
| 4 |
RNLX
Renalytix plc American Depositary Shares
RNLX
|
+$2.3M |
| 5 |
Curis
CRIS
|
+$1.54M |
Sector Composition
| 1 | Healthcare | 91.79% |
| 2 | Financials | 5.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BHVN
1
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $8.6M | 4.98% |
61,897
+5,271
| +9% | +$658K |
|
2
Veracyte
VCYT
$4.67B
| $8.34M | 4.83% |
179,548
+28,687
| +19% | +$1.25M |
|
|
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $8.13M | 4.71% |
45,941
+8,188
| +22% | +$1.32M |
|
|
MRUS
4
DELISTED
Merus
MRUS
| $7.61M | 4.41% |
345,964
+25,149
| +8% | +$539K |
|
|
AMYT
5
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
| $6.22M | 3.6% |
516,221
+59,684
| +13% | +$674K |
|
|
HZNP
6
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $5.75M | 3.33% |
52,469
+2,434
| +5% | +$253K |
|
|
7
Cogent Biosciences
COGT
$6.57B
| $5.7M | 3.3% |
677,900
+479,655
| +242% | +$3.68M |
|
8
Immatics
IMTX
$1.3B
| $5.69M | 3.3% |
437,866
+148,458
| +51% | +$1.89M |
|
|
9
Fulcrum Therapeutics
FULC
$239M
| $5.24M | 3.04% |
+185,691
| New | +$3.52M |
|
|
10
NextCure
NXTC
$22.7M
| $4.86M | 2.82% |
60,109
+36,317
| +153% | +$3.18M |
|
11
Insmed
INSM
$23.5B
| $4.81M | 2.79% |
174,588
-2,845
| -2% | -$74.6K |
|
|
RACB
12
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
| $4.66M | 2.7% |
473,396
-22,459
| -5% | -$222K |
|
13
United Therapeutics
UTHR
$22.2B
| $3.91M | 2.27% |
21,189
+5,900
| +39% | +$1.16M |
|
|
ITCI
14
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $3.8M | 2.2% |
101,890
-11,368
| -10% | -$395K |
|
|
15
Cerus
CERS
$625M
| $3.77M | 2.19% |
619,369
+600,678
| +3,214% | +$3.5M |
|
|
IMGN
16
DELISTED
Immunogen Inc
IMGN
| $3.69M | 2.14% |
649,919
-177,668
| -21% | -$1.03M |
|
|
SRRA
17
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $3.58M | 2.08% |
163,486
+24,181
| +17% | +$484K |
|
|
MORF
18
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $3.27M | 1.89% |
57,704
-46,154
| -44% | -$2.79M |
|
|
ITOS
19
DELISTED
iTeos Therapeutics
ITOS
| $3.16M | 1.83% |
116,931
+41,420
| +55% | +$1.08M |
|
20
Aclaris Therapeutics
ACRS
$757M
| $3.12M | 1.81% |
173,327
-15,392
| -8% | -$247K |
|
|
21
Arvinas
ARVN
$534M
| $3.06M | 1.77% |
+37,249
| New | +$3.29M |
|
|
CYPH
22
Cypherpunk Technologies Inc
CYPH
$83M
| $2.49M | 1.44% |
+62,000
| New | +$1.17M |
|
23
Halozyme
HALO
$8.89B
| $2.45M | 1.42% |
60,170
-6,503
| -10% | -$272K |
|
|
BLU
24
DELISTED
BELLUS Health Inc.
BLU
| $2.24M | 1.3% |
365,000
+155,067
| +74% | +$588K |
|
25
MoonLake Immunotherapeutics
MLTX
$1.66B
| $2.22M | 1.29% |
223,906
-10,114
| -4% | -$101K |
|
Similar funds
BOTOTLSJU
EFG
LA
EPIMS
CFP
USAA
OMC
AIA